Turbine joins Multimodal AI-ready data collaboration to train Virtual Assays in immune biology
Read more

Publications

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors 
Publication

Orsolya Papp, Viktória Jordán, Szabolcs Hetey, Róbert Balázs, Árpád Bartha, Nóra N. Ordasi, Sebestyén Kamp, Bálint Farkas, Jay Mettetal, Jonathan R. Dry, Duncan Young, Ben Sidders, Krishna C. Bulusu, Daniel V. Veres

Combination therapy is well established as a key intervention strategy for cancer treatment, with the potential to overcome monotherapy resistance and deliver a more durable efficacy. However, given the scale of unexplored potential target space and the resulting combinatorial explosion, identifying efficacious drug combinations is a critical unmet need that is still… read more

The Simulated Cell™ identifies LIG4 as a novel target in PARPi resistance via the modulation of NHEJ deficiency 
Poster

Csilla Laczka, Noémi Sándor, Iván Fekete, Dorottya Németh-Lukács, Orsolya Papp, Boldizsár Elek, Dániel Veres

Poly (ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair and an approved target in various homologous recombination (HR)-deficient tumors, including breast, ovarian, pancreatic and lung cancer. However, after initial responsiveness, tumors often develop resistance toward PARP inhibitors (PARPi). One of the major mechanisms of PARPi resistance is the suppression of the non-homologous… read more

Simulation driven identification of combinations for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated <em>in vivo</em> 
Poster

Boldizsár Elek, Anne Vaslin Chessex, Luke Piggott, Orsolya Papp, Iván Fekete and Dániel Veres

Debio 0123 is a novel, orally-available, selective ATP-competitive WEE1 inhibitor with potential as a best-in-class, brain-penetrant treatment being evaluated in Phase I trials for solid tumors. WEE1, a tyrosine kinase activated by DNA damage, acts at the S-phase and G2/M checkpoints to facilitate DNA repair before mitosis. read more

NEK1 is involved in tumor growth through altered immune signaling 
Poster

M.V. Ruiz-Pérez, I. Gáspár, I. Fekete, C. Szántai-Kis, S. Connolly, B. Elek, M. Djurec, C. Hegedüs, I. Taisz, D. Veres

Turbine’s Simulated Cell™ platform models cancer cell signaling to predict cell viability and to identify novel drug targets. By simulating perturbations of the DNA-damage response (DDR) pathway, we identified NEK1 as a cancer dependency in certain molecular contexts. NEK1 is part of the NIMA-related kinase family, involved in DDR, cell cycle, and… read more

The EFFECT benchmark suite: measuring cancer sensitivity prediction performance – without the bias 
Preprint

Bence Szalai, Imre Gaspar, Valer Kaszas, Laszlo Mero, Milan Sztilkovics, Kristof Z. Szalay

Creating computational biology models applicable to industry is much more difficult than it appears. There is a major gap between a model that looks good on paper and a model that performs well in the drug discovery process. We are trying to shrink this gap by introducing the Evaluation Framework For predicting… read more

The EFFECT Benchmark Suite: Measuring cancer sensitivity prediction performance – without bias 
PosterTRAIL

Bence Szalai, Imre Gáspár, Valér Kaszás, László Mérő, Milán Sztilkovics, Kristóf Z. Szalay

Accurate benchmarking of computational models is vital for the identification of the best-performing ones. However, these benchmarks, especially in biology, are rather ad-hoc and seldom pre-defined and standardized. We developed the Evaluation Framework For predicting Efficiency of Cancer Treatment (EFFECT) benchmark suite based on the DepMap and GDSC data sets to facilitate… read more